<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028296</url>
  </required_header>
  <id_info>
    <org_study_id>I300005627</org_study_id>
    <nct_id>NCT05028296</nct_id>
  </id_info>
  <brief_title>Novel Mucosal Sampling Technology for Gastric Neoplasia: Wide-area Trans-epithelial Gastric Sampling for the Detection of Premalignant Lesions and Early Gastric Cancer</brief_title>
  <official_title>Novel Mucosal Sampling Technology for Gastric Neoplasia: Wide-area Trans-epithelial Gastric Sampling for the Detection of Premalignant Lesions and Early Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to compare the diagnostic yields of the WATS approach versus&#xD;
      the updated Sydney protocol (five standard biopsies in the three gastric regions).&#xD;
&#xD;
      â€¢ We hypothesize that the WATS technology will increase the overall diagnostic yield up to&#xD;
      35% of gastric premalignant lesions and early gastric cancer.&#xD;
&#xD;
      To explore the performance of the existing and novel biomarkers, including the IHCs p53 and&#xD;
      MUC2.&#xD;
&#xD;
        -  We anticipate concordance of the existing biomarkers as adjuncts to the diagnosis.&#xD;
&#xD;
        -  To accomplish this aim, we will analyze current biomarkers on all study subjects (Aim&#xD;
           1), as well as explore novel gastric biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We expect that this study will advance the field of gastric cancer early detection,&#xD;
      surveillance and prevention.&#xD;
&#xD;
        -  We hypothesize that a streamlined clinical protocol and SOP will emerge.&#xD;
&#xD;
        -  We anticipate that this approach will enhance clinical practice as it has in Barrett's&#xD;
           esophagus. This comes at a time when endoscopy imaging capabilities are advancing to&#xD;
           eventually permit targeted sampling by WATS.&#xD;
&#xD;
        -  We expect novel biomarkers to be incorporated into WATS clinical practice for gastric&#xD;
           neoplasia, based upon discovery (Aim 2).&#xD;
&#xD;
        -  We will advance the implementation science as we elucidate the barriers to gastric&#xD;
           cancer screening in the diverse populations in this study (Scarinci).&#xD;
&#xD;
        -  We fully expect this study to alter clinical practice and to develop into a variety of&#xD;
           ongoing funding pathways.&#xD;
&#xD;
      We hypothesize that the WATS will increase the overall histology diagnostic yield by up to&#xD;
      35% and the specific diagnostic yield of gastric intestinal metaplasia (from 20% to 30%), and&#xD;
      dysplasia (from 2% to 10%) and early gastric cancer (from 1% to 3%). The examination of novel&#xD;
      WATS biomarkers (IHCs) such as gH2AX and the mucins (Aim 2) is exploratory.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the diagnostic yields of the WATS approach versus the updated Sydney protocol</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To explore the performance of the existing and novel biomarkers, including the IHCs p53 and MUC2</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Patients Scheduled for Standard of Care Upper Endoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WATS Sampling</intervention_name>
    <description>WATS sampling and analysis in the stomach compartments (antrium, incisira, corpus)</description>
    <arm_group_label>Patients Scheduled for Standard of Care Upper Endoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with indication for upper endoscopy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Morgan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Douglas Morgan, MD</last_name>
    <phone>205-975-9564</phone>
    <email>drmorgan@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Douglas Morgan, MD</last_name>
      <phone>205-934-0884</phone>
      <email>morgandr@uab.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Douglas Morgan MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

